SVRA Savara4.68+0.51 (+12.2%)
Premarket Decliner
SVRA Savara2.84-0.09-3.1%
Premarket:1.81-1.03 (-36.3%)
Savara Receives Refusal to File (RTF) Letter From the U.S. Food and Drug Administration (FDA) for the Biologics License Application (BLA) for MOLBREEVI* to Treat Patients With Autoimmune Pulmonary Alveolar Proteinosis (autoimmune PAP)
Business WireTue, 27-May 8:05 AM
SVRA Savara4.06+0.26 (+6.8%)
SVRA 4.12+0.32 (+8.4%)Savara
SVRA Savara3.61-0.27 (-7.0%)